{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:32:00Z","timestamp":1704702720208},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00105-023-05209-3","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T15:58:48Z","timestamp":1692374328000},"page":"687-695","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pemphigoiderkrankungen bei \u00e4lteren Menschen","Pemphigoid diseases in older adults"],"prefix":"10.1007","volume":"74","author":[{"given":"Eva Lotta","family":"Moderegger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie J.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian D.","family":"Sadik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"5209_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai\u00a0M, Ikeda\u00a0S, Hashimoto\u00a0T et al (2017) A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J\u00a0Dermatol Sci 85:77\u201384","journal-title":"J Dermatol Sci"},{"key":"5209_CR2","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram\u00a0F, Brocker\u00a0EB, Zillikens\u00a0D et\u00a0al (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J\u00a0Dtsch Dermatol Ges 7:434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/exd.13415","volume":"26","author":"K Bieber","year":"2017","unstructured":"Bieber\u00a0K, Koga\u00a0H, Nishie\u00a0W (2017) In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases. Exp Dermatol 26:1163\u20131170","journal-title":"Exp Dermatol"},{"key":"5209_CR4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","volume":"36","author":"L Borradori","year":"2022","unstructured":"Borradori\u00a0L, Van Beek\u00a0N, Feliciani\u00a0C et\u00a0al (2022) Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J\u00a0Eur Acad Dermatol Venereol 36:1689\u20131704","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR5","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1073\/pnas.0809230106","volume":"106","author":"T Dainichi","year":"2009","unstructured":"Dainichi\u00a0T, Kurono\u00a0S, Ohyama\u00a0B et al (2009) Anti-laminin gamma\u20111 pemphigoid. Proc Natl Acad Sci U S\u00a0A 106:2800\u20132805","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5209_CR6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","volume":"167","author":"R Della Torre","year":"2012","unstructured":"Della Torre\u00a0R, Combescure\u00a0C, Cortes\u00a0B et\u00a0al (2012) Clinical presentation and diagnostic delay in bullous pemphigoid: a\u00a0prospective nationwide cohort. Br J Dermatol 167:1111\u20131117","journal-title":"Br J Dermatol"},{"key":"5209_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2007.00208.x","volume":"34","author":"A Dilling","year":"2007","unstructured":"Dilling\u00a0A, Rose\u00a0C, Hashimoto\u00a0T et al (2007) Anti-p200 pemphigoid: a\u00a0novel autoimmune subepidermal blistering disease. J\u00a0Dermatol 34:1\u20138","journal-title":"J Dermatol"},{"key":"5209_CR8","doi-asserted-by":"crossref","first-page":"103036","DOI":"10.1016\/j.autrev.2022.103036","volume":"21","author":"G Du","year":"2022","unstructured":"Du\u00a0G, Patzelt\u00a0S, Van Beek\u00a0N et\u00a0al (2022) Mucous membrane pemphigoid. Autoimmun Rev 21:103036","journal-title":"Autoimmun Rev"},{"key":"5209_CR9","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","volume":"357","author":"CA Egan","year":"2001","unstructured":"Egan\u00a0CA, Lazarova\u00a0Z, Darling\u00a0TN et al (2001) Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 357:1850\u20131851","journal-title":"Lancet"},{"key":"5209_CR10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/exd.13401","volume":"26","author":"AK Forsti","year":"2017","unstructured":"Forsti\u00a0AK, Huilaja\u00a0L, Schmidt\u00a0E et al (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26:1228\u20131234","journal-title":"Exp Dermatol"},{"key":"5209_CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jaad.2014.02.036","volume":"71","author":"S Goletz","year":"2014","unstructured":"Goletz\u00a0S, Hashimoto\u00a0T, Zillikens\u00a0D et al (2014) Anti-p200 pemphigoid. J\u00a0Am Acad Dermatol 71:185\u2013191","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjd.17202","volume":"180","author":"S Goletz","year":"2019","unstructured":"Goletz\u00a0S, Probst\u00a0C, Komorowski\u00a0L et\u00a0al (2019) A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol 180:149\u2013156","journal-title":"Br J Dermatol"},{"key":"5209_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2133.2010.10056.x","volume":"164","author":"S Groth","year":"2011","unstructured":"Groth\u00a0S, Recke\u00a0A, Vafia\u00a0K et al (2011) Development of a\u00a0simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 164:76\u201382","journal-title":"Br J Dermatol"},{"key":"5209_CR14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","volume":"137","author":"EN Heppe","year":"2017","unstructured":"Heppe\u00a0EN, Tofern\u00a0S, Schulze\u00a0FS et\u00a0al (2017) Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and Immunopathological characteristics of the human disease. J\u00a0Invest Dermatol 137:1709\u20131718","journal-title":"J Invest Dermatol"},{"key":"5209_CR15","first-page":"1530","volume":"20","author":"SC Hofmann","year":"2022","unstructured":"Hofmann\u00a0SC, Gunther\u00a0C, Bockle\u00a0BC et al (2022) S2k-Leitlinie zur Diagnostik und Therapie des Schleimhautpemphigoids. J\u00a0Dtsch Dermatol Ges 20:1530\u20131552","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaad.2020.07.076","volume":"84","author":"MM Holtsche","year":"2021","unstructured":"Holtsche\u00a0MM, Goletz\u00a0S, Von Georg\u00a0A et al (2021) Serologic characterization of anti-p200 pemphigoid: Epitope spreading as a\u00a0common phenomenon. J\u00a0Am Acad Dermatol 84:1155\u20131157","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00105-019-4376-x","volume":"70","author":"MM Holtsche","year":"2019","unstructured":"Holtsche\u00a0MM, Goletz\u00a0S, Zillikens\u00a0D (2019) Anti-p200 pemphigoid. Hautarzt 70:271\u2013276","journal-title":"Hautarzt"},{"key":"5209_CR18","doi-asserted-by":"crossref","first-page":"adv00410","DOI":"10.2340\/00015555-3748","volume":"101","author":"MM Holtsche","year":"2021","unstructured":"Holtsche\u00a0MM, Van Beek\u00a0N, Kunstner\u00a0A et\u00a0al (2021) Diagnostic value and practicability of serration pattern analysis by direct immunofluorescence microscopy in pemphigoid diseases. Acta Derm Venereol 101:adv410","journal-title":"Acta Derm Venereol"},{"key":"5209_CR19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","volume":"69","author":"MM Holtsche","year":"2018","unstructured":"Holtsche\u00a0MM, Zillikens\u00a0D, Schmidt\u00a0E (2018) Mucous membrane pemphigoid. Hautarzt 69:67\u201383","journal-title":"Hautarzt"},{"key":"5209_CR20","first-page":"1109","volume":"16","author":"F Hubner","year":"2018","unstructured":"Hubner\u00a0F, Kasperkiewicz\u00a0M, Knuth-Rehr\u00a0D et al (2018) Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J\u00a0Dtsch Dermatol Ges 16:1109\u20131118","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR21","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F Hubner","year":"2016","unstructured":"Hubner\u00a0F, Recke\u00a0A, Zillikens\u00a0D et\u00a0al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136:2495\u20132498","journal-title":"J Invest Dermatol"},{"key":"5209_CR22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","volume":"10","author":"K Izumi","year":"2019","unstructured":"Izumi\u00a0K, Bieber\u00a0K, Ludwig\u00a0RJ (2019) Current clinical trials in pemphigus and pemphigoid. Front Immunol 10:978","journal-title":"Front Immunol"},{"key":"5209_CR23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3389\/fimmu.2018.00488","volume":"9","author":"CM Karsten","year":"2018","unstructured":"Karsten\u00a0CM, Beckmann\u00a0T, Holtsche\u00a0MM et\u00a0al (2018) Tissue destruction in bullous pemphigoid can be complement independent and may be mitigated by C5aR2. Front Immunol 9:488","journal-title":"Front Immunol"},{"key":"5209_CR24","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1002\/cpph.55","volume":"84","author":"A Kasprick","year":"2019","unstructured":"Kasprick\u00a0A, Bieber\u00a0K, Ludwig\u00a0RJ (2019) Drug discovery for pemphigoid diseases. Curr Protoc Pharmacol 84:e55","journal-title":"Curr Protoc Pharmacol"},{"key":"5209_CR25","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2011.12.032","volume":"68","author":"L Komorowski","year":"2013","unstructured":"Komorowski\u00a0L, Muller\u00a0R, Vorobyev\u00a0A et\u00a0al (2013) Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J\u00a0Am Acad Dermatol 68:e89\u2013e95","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR26","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fimmu.2019.02466","volume":"10","author":"K Kridin","year":"2019","unstructured":"Kridin\u00a0K, Ahmed\u00a0AR (2019) Anti-p200 pemphigoid: a systematic review. Front Immunol 10:2466","journal-title":"Front Immunol"},{"key":"5209_CR27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","volume":"5","author":"K Kridin","year":"2018","unstructured":"Kridin\u00a0K, Ludwig\u00a0RJ (2018) The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne) 5:220","journal-title":"Front Med (Lausanne)"},{"key":"5209_CR28","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","volume":"30","author":"YC Lai","year":"2016","unstructured":"Lai\u00a0YC, Yew\u00a0YW, Lambert\u00a0WC (2016) Bullous pemphigoid and its association with neurological diseases: a\u00a0systematic review and meta-analysis. J\u00a0Eur Acad Dermatol Venereol 30:2007\u20132015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR29","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan\u00a0SM, Smeeth\u00a0L, Hubbard\u00a0R et\u00a0al (2008) Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study. BMJ 337:a180","journal-title":"BMJ"},{"key":"5209_CR30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2019.03.077","volume":"81","author":"I Lau","year":"2019","unstructured":"Lau\u00a0I, Goletz\u00a0S, Holtsche\u00a0MM et al (2019) Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin. J\u00a0Am Acad Dermatol 81:1195\u20131197","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jdv.15961","volume":"34","author":"R Laufer Britva","year":"2020","unstructured":"Laufer Britva\u00a0R, Amber\u00a0KT, Cohen\u00a0AD et al (2020) Treatment and clinical outcomes in anti-p200 pemphigoid: a\u00a0systematic review. J\u00a0Eur Acad Dermatol Venereol 34:465\u2013472","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","volume":"156","author":"SD Liu","year":"2020","unstructured":"Liu\u00a0SD, Chen\u00a0WT, Chi\u00a0CC (2020) Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol 156:891\u2013900","journal-title":"JAMA Dermatol"},{"key":"5209_CR33","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"G Marazza","year":"2009","unstructured":"Marazza\u00a0G, Pham\u00a0HC, Scharer\u00a0L et al (2009) Incidence of bullous pemphigoid and pemphigus in Switzerland: a\u00a02-year prospective study. Br J Dermatol 161:861\u2013868","journal-title":"Br J Dermatol"},{"key":"5209_CR34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jaad.2017.11.029","volume":"78","author":"JM Meijer","year":"2018","unstructured":"Meijer\u00a0JM, Atefi\u00a0I, Diercks\u00a0GFH et\u00a0al (2018) Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J\u00a0Am Acad Dermatol 78:754\u2013759.e6","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2016.1099","volume":"152","author":"JM Meijer","year":"2016","unstructured":"Meijer\u00a0JM, Diercks\u00a0GF, Schmidt\u00a0E et al (2016) Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol 152:897\u2013904","journal-title":"JAMA Dermatol"},{"key":"5209_CR36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell\u00a0DF, Daniel\u00a0BS, Joly\u00a0P et\u00a0al (2012) Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J\u00a0Am Acad Dermatol 66:479\u2013485","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","volume":"72","author":"DF Murrell","year":"2015","unstructured":"Murrell\u00a0DF, Marinovic\u00a0B, Caux\u00a0F et\u00a0al (2015) Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J\u00a0Am Acad Dermatol 72:168\u2013174","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR38","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.jid.2021.04.009","volume":"141","author":"S Murthy","year":"2021","unstructured":"Murthy\u00a0S, Schilf\u00a0P, Patzelt\u00a0S et\u00a0al (2021) Dapsone suppresses disease in preclinical murine models of pemphigoid diseases. J\u00a0Invest Dermatol 141:2587\u20132595.e2","journal-title":"J Invest Dermatol"},{"key":"5209_CR39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/CCID.S324331","volume":"15","author":"JJ Padniewski","year":"2022","unstructured":"Padniewski\u00a0JJ, Shaver\u00a0RL, Schultz\u00a0B et\u00a0al (2022) Patient quality of life improvement in bullous disease: a review of primary literature and considerations for the clinician. Clin Cosmet Investig Dermatol 15:27\u201342","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"5209_CR40","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/jdv.17397","volume":"35","author":"H Rashid","year":"2021","unstructured":"Rashid\u00a0H, Lamberts\u00a0A, Borradori\u00a0L et\u00a0al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology\u2014Part I. J\u00a0Eur Acad Dermatol Venereol 35:1750\u20131764","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2020.02.020","volume":"145","author":"CD Sadik","year":"2020","unstructured":"Sadik\u00a0CD, Schmidt\u00a0E, Zillikens\u00a0D et\u00a0al (2020) Recent progresses and perspectives in autoimmune bullous diseases. J\u00a0Allergy Clin Immunol 145:1145\u20131147","journal-title":"J Allergy Clin Immunol"},{"key":"5209_CR42","first-page":"713","volume":"13","author":"E Schmidt","year":"2015","unstructured":"Schmidt\u00a0E, Goebeler\u00a0M, Hertl\u00a0M et\u00a0al (2015) S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 13:713\u2013727","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR43","volume-title":"Rook\u2019s textbook of dermatology, part 3","author":"EGR Schmidt","year":"2023","unstructured":"Schmidt\u00a0EGR (2023) Immunobullous disorders. In: Griffith\u00a0CBJ, Bleiker\u00a0T, Hussain\u00a0W, Simposn\u00a0RS (Hrsg) Rook\u2019s textbook of dermatology, part 3. Wiley-Blackwell, Chichester"},{"key":"5209_CR44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00347-023-01858-w","volume":"120","author":"E Schmidt","year":"2023","unstructured":"Schmidt\u00a0E, Patzelt\u00a0S (2023) Immunopathogenesis of mucous membrane pemphigoid. Ophthalmologie 120:462\u2013471","journal-title":"Ophthalmologie"},{"key":"5209_CR45","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/jdv.17395","volume":"35","author":"E Schmidt","year":"2021","unstructured":"Schmidt\u00a0E, Rashid\u00a0H, Marzano\u00a0AV et\u00a0al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology\u2014Part II. J\u00a0Eur Acad Dermatol Venereol 35:1926\u20131948","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR46","first-page":"516","volume":"18","author":"E Schmidt","year":"2020","unstructured":"Schmidt\u00a0E, Sticherling\u00a0M, Sardy\u00a0M et\u00a0al (2020) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid: 2019 update. J\u00a0Dtsch Dermatol Ges 18:516\u2013526","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt\u00a0E, Zillikens\u00a0D (2013) Pemphigoid diseases. Lancet 381:320\u2013332","journal-title":"Lancet"},{"key":"5209_CR48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaad.2017.05.016","volume":"77","author":"I Shimanovich","year":"2017","unstructured":"Shimanovich\u00a0I, Nitz\u00a0JM, Zillikens\u00a0D (2017) Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid. J\u00a0Am Acad Dermatol 77:700\u2013705.e3","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1439-0353.2004.03047.x","volume":"2","author":"I Shimanovich","year":"2004","unstructured":"Shimanovich\u00a0I, Rose\u00a0C, Hirako\u00a0Y et al (2004) Anti-p200 pemphigoid\u2014a new bullous autoimmune dermatosis. J\u00a0Dtsch Dermatol Ges 2:7\u201314","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR50","first-page":"1289","volume":"19","author":"S Stander","year":"2021","unstructured":"Stander\u00a0S, Schmidt\u00a0E, Zillikens\u00a0D et\u00a0al (2021) Immunological features and factors associated with mucocutaneous bullous pemphigoid\u2014a\u00a0retrospective cohort study. J\u00a0Dtsch Dermatol Ges 19:1289\u20131295","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR51","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling\u00a0M, Franke\u00a0A, Aberer\u00a0E et\u00a0al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177:1299\u20131305","journal-title":"Br J Dermatol"},{"key":"5209_CR52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2011.03.008","volume":"29","author":"H Ujiie","year":"2011","unstructured":"Ujiie\u00a0H, Nishie\u00a0W, Shimizu\u00a0H (2011) Pathogenesis of bullous pemphigoid. Dermatol Clin 29:439\u2013446","journal-title":"Dermatol Clin"},{"key":"5209_CR53","doi-asserted-by":"crossref","first-page":"875492","DOI":"10.3389\/fmed.2022.875492","volume":"9","author":"H Ujiie","year":"2022","unstructured":"Ujiie\u00a0H, Rosmarin\u00a0D, Schon\u00a0MP et al (2022) Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front Med (Lausanne) 9:875492","journal-title":"Front Med (Lausanne)"},{"key":"5209_CR54","doi-asserted-by":"crossref","first-page":"e41769","DOI":"10.1371\/journal.pone.0041769","volume":"7","author":"K Vafia","year":"2012","unstructured":"Vafia\u00a0K, Groth\u00a0S, Beckmann\u00a0T et al (2012) Pathogenicity of autoantibodies in anti-p200 pemphigoid. PLoS One 7:e41769","journal-title":"PLoS One"},{"key":"5209_CR55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1001\/jamadermatol.2021.4773","volume":"158","author":"N Van Beek","year":"2022","unstructured":"Van Beek\u00a0N, Kridin\u00a0K, Buhler\u00a0E et al (2022) Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol 158:84\u201389","journal-title":"JAMA Dermatol"},{"key":"5209_CR56","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jaad.2020.01.049","volume":"83","author":"N Van Beek","year":"2020","unstructured":"Van Beek\u00a0N, Kruger\u00a0S, Fuhrmann\u00a0T et\u00a0al (2020) Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. J\u00a0Am Acad Dermatol 83:1315\u20131322","journal-title":"J Am Acad Dermatol"},{"key":"5209_CR57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","volume":"153","author":"N Van Beek","year":"2017","unstructured":"Van Beek\u00a0N, Luttmann\u00a0N, Huebner\u00a0F et\u00a0al (2017) Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153:30\u201338","journal-title":"JAMA Dermatol"},{"key":"5209_CR58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-7-49","volume":"7","author":"N Van Beek","year":"2012","unstructured":"Van Beek\u00a0N, Rentzsch\u00a0K, Probst\u00a0C et al (2012) Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 7:49","journal-title":"Orphanet J Rare Dis"},{"key":"5209_CR59","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/jdv.17107","volume":"35","author":"N Van Beek","year":"2021","unstructured":"Van Beek\u00a0N, Weidinger\u00a0A, Schneider\u00a0SW et al (2021) Incidence of pemphigoid diseases in Northern Germany in 2016\u2014first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J\u00a0Eur Acad Dermatol Venereol 35:1197\u20131202","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5209_CR60","first-page":"1077","volume":"16","author":"N Van Beek","year":"2018","unstructured":"Van Beek\u00a0N, Zillikens\u00a0D, Schmidt\u00a0E (2018) Diagnosis of autoimmune bullous diseases. J\u00a0Dtsch Dermatol Ges 16:1077\u20131091","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR61","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams\u00a0HC, Wojnarowska\u00a0F, Kirtschig\u00a0G et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a\u00a0pragmatic, non-inferiority, randomised controlled trial. Lancet 389:1630\u20131638","journal-title":"Lancet"},{"key":"5209_CR62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fmed.2018.00296","volume":"5","author":"M Witte","year":"2018","unstructured":"Witte\u00a0M, Zillikens\u00a0D, Schmidt\u00a0E (2018) Diagnosis of autoimmune blistering diseases. Front Med (Lausanne) 5:296","journal-title":"Front Med (Lausanne)"},{"key":"5209_CR63","first-page":"285","volume":"21","author":"K Yilmaz","year":"2023","unstructured":"Yilmaz\u00a0K, Hammers\u00a0CM, Boch\u00a0K et\u00a0al (2023) Immunoglobulin\u00a0M mucous membrane pemphigoid. J\u00a0Dtsch Dermatol Ges 21:285\u2013287","journal-title":"J Dtsch Dermatol Ges"},{"key":"5209_CR64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/1523-1747.ep12337492","volume":"109","author":"D Zillikens","year":"1997","unstructured":"Zillikens\u00a0D, Rose\u00a0PA, Balding\u00a0SD et\u00a0al (1997) Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J\u00a0Invest Dermatol 109:573\u2013579","journal-title":"J Invest Dermatol"},{"key":"5209_CR65","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archderm.1995.01690200097021","volume":"131","author":"D Zillikens","year":"1995","unstructured":"Zillikens\u00a0D, Wever\u00a0S, Roth\u00a0A et\u00a0al (1995) Incidence of autoimmune subepidermal blistering dermatoses in a\u00a0region of central Germany. Arch Dermatol 131:957\u2013958","journal-title":"Arch Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05209-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05209-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05209-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T14:03:43Z","timestamp":1693922623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05209-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5209"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05209-3","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.L.\u00a0Moderegger, M.J.\u00a0Schmitz, R.J.\u00a0Ludwig und C.D.\u00a0Sadik geben an, dass kein Interessenkonflikt besteht. E.\u00a0Schmidt hat wissenschaftliche Kooperationen mit Euroimmun, UCB, Incyte, Biotest, argenx, Dompe, Admirx, Biondis, Fresenius Medical Care, Pharmaxis, Alpine Immune, Bayer, CSL, AstraZeneca und Pincell und Patente mit Euroimmun und Dompe. E.\u00a0Schmidt bekam Honorare und\/oder Reisekostenerstattung von Biotest, argenx, Fresenius Medical Care, AstraZeneca, Leo, Chugai, Sanofi und Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}